Trial Profile
Radiotherapy (intensity-modulated radiation therapy [IMRT]), Erbitux [cetuximab] And CHemotherapy [carboplatin + fluorouracil] for unresectable carcinomas of head and neck
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2022
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Carboplatin; Fluorouracil
- Indications Head and neck cancer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms REACH
- 22 Jul 2008 New trial record.